Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
BIOCYTOGEN (02315.HK) Partner NEOK Bio's Bispecific ADC NEOK002 Approved for US Clinical Trial
Recommend 1 Positive 1 Negative 0 |
||||
|
||||
|
BIOCYTOGEN-B (02315.HK) announced that its partner, NEOK Bio, Inc., has recently received approval from the United States Food and Drug Administration for the investigational new drug clinical trial application of NEOK002. NEOK002 is an antibody-drug conjugate ("ADC") targeting EGFR/MUC1, intended for the treatment of solid tumors. NEOK Bio plans to initiate a Phase I clinical trial in the second quarter of 2026 and expects to release preliminary clinical data in 2027. (hc/w) AASTOCKS Financial News URL: www.aastocks.com Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
|
||||
Copied to Clipboard
 |
||||
